Home » Stocks » CRL

Charles River Laboratories International, Inc. (CRL)

Stock Price: $222.00 USD -7.26 (-3.17%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 11.03B
Revenue (ttm) 2.75B
Net Income (ttm) 271.36M
Shares Out 49.68M
EPS (ttm) 5.44
PE Ratio 40.81
Forward PE 28.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $222.00
Previous Close $229.26
Change ($) -7.26
Change (%) -3.17%
Day's Open 225.00
Day's Range 221.90 - 225.25
Day's Volume 338,400
52-Week Range 95.58 - 250.29

More Stats

Market Cap 11.03B
Enterprise Value 13.03B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 49.68M
Float 48.88M
EPS (basic) 5.52
EPS (diluted) 5.44
FCF / Share 8.39
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.45%
FCF Yield 3.77%
Payout Ratio n/a
Shares Short 632,579
Short Ratio 1.98
Short % of Float 1.29%
Beta 1.13
PE Ratio 40.81
Forward PE 28.25
P/FCF Ratio 26.52
PS Ratio 4.01
PB Ratio 6.63
Revenue 2.75B
Operating Income 372.64M
Net Income 271.36M
Free Cash Flow 415.90M
Net Cash -2.01B
Net Cash / Share -40.38
Gross Margin 35.11%
Operating Margin 13.56%
Profit Margin 9.90%
FCF Margin 15.13%
ROA 4.98%
ROE 16.73%
ROIC 10.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (19)

Buy 15
Overweight 1
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$245.69*
(10.67% upside)
Low
203
Current: $222.00
High
281
Target: 245.69
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,6212,2661,8581,6811,3631,2981,1661,1301,1431,133
Revenue Growth15.67%21.99%10.48%23.34%5.06%11.34%3.19%-1.15%0.81%-
Gross Profit958840701644531473395392402385
Operating Income351331288238206178151166174-299
Net Income25222612315514912710397.30110-337
Shares Outstanding48.7347.9547.4847.0146.6246.9248.1248.5549.4457.72
Earnings Per Share5.074.622.543.233.132.662.122.012.14-5.38
EPS Growth9.74%81.89%-21.36%3.19%17.67%25.47%5.47%-6.07%--
Operating Cash Flow481441318317307252209208207168
Capital Expenditures-141-140-82.43-55.29-63.25-56.93-39.15-47.53-49.14-42.86
Free Cash Flow340301236262244195170160158125
Cash & Equivalents23819516411811816015611068.91179
Total Debt2,0041,6681,1451,235863772664667718701
Net Cash / Debt-1,766-1,473-981-1,117-745-612-508-557-649-522
Assets4,6933,8562,9302,7122,0681,8711,6331,5861,5581,733
Liabilities3,0262,5181,8661,8581,3031,1669689831,0311,045
Book Value1,6351,3171,045837733672641601526687
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Charles River Laboratories International, Inc.
Country United States
Employees 17,100
CEO James C. Foster

Stock Information

Ticker Symbol CRL
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: CRL
IPO Date June 23, 2000

Description

Charles River Laboratories International, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.